Double stranded RNA (dsRNA) has multiple anti-tumor mechanisms. Over the past several decades, there have been numerous attempts to utilize synthetic dsRNA to control tumor growth in animal models and clinical trials. Recently, it has become clear that intracellular dsRNA is more effective than extracellular dsRNA on promoting apoptosis and orchestrating adaptive immune responses. To overcome the difficulty in delivering a large dose of synthetic dsRNA into tumors, we propose to deliver a replicase-based plasmid DNA, hypothesizing that the dsRNA generated by the replicase-based plasmid in tumor cells will inhibit tumor growth.

We evaluated the anti-tumor activity of a plasmid (pSIN-beta) that encodes the sindbis RNA replicase genes (nsp1-4) in mice with model tumors (TC-1 lung cancer cells or B16 melanoma cells) and compared it to a traditional pCMV-beta plasmid.

In cell culture, transfection of tumor cells with pSIN-beta generated dsRNA. In mice with model tumors, pSIN-beta more effectively delayed tumor growth than pCMV-beta, and in some cases, eradicated the tumors.

Replicase-based plasmid may be exploited to generate intracellular dsRNA to control tumor growth.

The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.